Celgene Corporation (CELG) PT Raised to $167.00

Celgene Corporation (NASDAQ:CELG) had its price target lifted by investment analysts at BMO Capital Markets from $160.00 to $167.00 in a research note issued on Tuesday. The brokerage currently has a “positive” rating on the biopharmaceutical company’s stock. BMO Capital Markets’ price target would indicate a potential upside of 22.16% from the stock’s current price.

Several other analysts have also recently issued reports on CELG. Cantor Fitzgerald set a $162.00 target price on shares of Celgene Corporation and gave the stock a “buy” rating in a research note on Monday. Oppenheimer Holdings, Inc. reiterated an “outperform” rating and issued a $175.00 target price on shares of Celgene Corporation in a research note on Wednesday, August 9th. Jefferies Group LLC reiterated a “buy” rating and issued a $160.00 target price on shares of Celgene Corporation in a research note on Monday. Vetr upgraded shares of Celgene Corporation from a “buy” rating to a “strong-buy” rating and set a $148.32 target price on the stock in a research note on Wednesday, August 16th. Finally, SunTrust Banks, Inc. reiterated a “buy” rating and issued a $150.00 target price on shares of Celgene Corporation in a research note on Friday, July 14th. Two research analysts have rated the stock with a sell rating, five have given a hold rating and twenty-two have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $151.10.

Celgene Corporation (NASDAQ:CELG) opened at 136.71 on Tuesday. Celgene Corporation has a 12 month low of $96.93 and a 12 month high of $147.17. The firm has a market capitalization of $106.96 billion, a P/E ratio of 42.34 and a beta of 1.89. The firm’s 50-day moving average is $141.03 and its 200 day moving average is $130.15.

Celgene Corporation (NASDAQ:CELG) last posted its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.61 by $0.21. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. The business had revenue of $3.27 billion for the quarter, compared to analysts’ expectations of $3.23 billion. During the same period in the prior year, the company posted $1.44 EPS. The business’s revenue for the quarter was up 18.7% compared to the same quarter last year. On average, analysts expect that Celgene Corporation will post $7.33 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Celgene Corporation (CELG) PT Raised to $167.00” was originally published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this news story on another site, it was stolen and republished in violation of US and international copyright & trademark laws. The correct version of this news story can be viewed at https://ledgergazette.com/2017/10/17/celgene-corporation-celg-pt-raised-to-167-00.html.

In other news, Director Ernest Mario sold 18,506 shares of Celgene Corporation stock in a transaction dated Thursday, August 10th. The shares were sold at an average price of $130.52, for a total transaction of $2,415,403.12. Following the sale, the director now owns 69,424 shares of the company’s stock, valued at approximately $9,061,220.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Gilla Kaplan sold 7,500 shares of Celgene Corporation stock in a transaction dated Wednesday, August 2nd. The shares were sold at an average price of $134.52, for a total transaction of $1,008,900.00. Following the sale, the director now directly owns 76,301 shares in the company, valued at approximately $10,264,010.52. The disclosure for this sale can be found here. Insiders have sold a total of 46,233 shares of company stock worth $6,268,259 in the last ninety days. Insiders own 0.95% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in the company. BlackRock Inc. boosted its stake in shares of Celgene Corporation by 5.7% during the 2nd quarter. BlackRock Inc. now owns 56,725,342 shares of the biopharmaceutical company’s stock valued at $7,366,919,000 after purchasing an additional 3,084,227 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Celgene Corporation by 3.1% during the 2nd quarter. Vanguard Group Inc. now owns 53,527,210 shares of the biopharmaceutical company’s stock valued at $6,951,579,000 after purchasing an additional 1,610,056 shares in the last quarter. State Street Corp boosted its stake in shares of Celgene Corporation by 2.3% during the 1st quarter. State Street Corp now owns 32,473,417 shares of the biopharmaceutical company’s stock valued at $4,040,668,000 after purchasing an additional 723,844 shares in the last quarter. Jennison Associates LLC boosted its stake in shares of Celgene Corporation by 1.2% during the 2nd quarter. Jennison Associates LLC now owns 13,415,734 shares of the biopharmaceutical company’s stock valued at $1,742,301,000 after purchasing an additional 156,864 shares in the last quarter. Finally, FMR LLC boos

Several other analysts have also recently issued reports on CELG. Cantor Fitzgerald set a $162.00 target price on shares of Celgene Corporation and gave the stock a “buy” rating in a research note on Monday. Oppenheimer Holdings, Inc. reiterated an “outperform” rating and issued a $175.00 target price on shares of Celgene Corporation in a research note on Wednesday, August 9th. Jefferies Group LLC reiterated a “buy” rating and issued a $160.00 target price on shares of Celgene Corporation in a research note on Monday. Vetr upgraded shares of Celgene Corporation from a “buy” rating to a “strong-buy” rating and set a $148.32 target price on the stock in a research note on Wednesday, August 16th. Finally, SunTrust Banks, Inc. reiterated a “buy” rating and issued a $150.00 target price on shares of Celgene Corporation in a research note on Friday, July 14th. Two research analysts have rated the stock with a sell rating, five have given a hold rating and twenty-two have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $151.10.

Celgene Corporation (NASDAQ:CELG) opened at 136.71 on Tuesday. Celgene Corporation has a 12 month low of $96.93 and a 12 month high of $147.17. The firm has a market capitalization of $106.96 billion, a P/E ratio of 42.34 and a beta of 1.89. The firm’s 50-day moving average is $141.03 and its 200 day moving average is $130.15.

Celgene Corporation (NASDAQ:CELG) last posted its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.61 by $0.21. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. The business had revenue of $3.27 billion for the quarter, compared to analysts’ expectations of $3.23 billion. During the same period in the prior year, the company posted $1.44 EPS. The business’s revenue for the quarter was up 18.7% compared to the same quarter last year. On average, analysts expect that Celgene Corporation will post $7.33 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Celgene Corporation (CELG) PT Raised to $167.00” was originally published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this news story on another site, it was stolen and republished in violation of US and international copyright & trademark laws. The correct version of this news story can be viewed at https://ledgergazette.com/2017/10/17/celgene-corporation-celg-pt-raised-to-167-00.html.

In other news, Director Ernest Mario sold 18,506 shares of Celgene Corporation stock in a transaction dated Thursday, August 10th. The shares were sold at an average price of $130.52, for a total transaction of $2,415,403.12. Following the sale, the director now owns 69,424 shares of the company’s stock, valued at approximately $9,061,220.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Gilla Kaplan sold 7,500 shares of Celgene Corporation stock in a transaction dated Wednesday, August 2nd. The shares were sold at an average price of $134.52, for a total transaction of $1,008,900.00. Following the sale, the director now directly owns 76,301 shares in the company, valued at approximately $10,264,010.52. The disclosure for this sale can be found here. Insiders have sold a total of 46,233 shares of company stock worth $6,268,259 in the last ninety days. Insiders own 0.95% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in the company. BlackRock Inc. boosted its stake in shares of Celgene Corporation by 5.7% during the 2nd quarter. BlackRock Inc. now owns 56,725,342 shares of the biopharmaceutical company’s stock valued at $7,366,919,000 after purchasing an additional 3,084,227 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Celgene Corporation by 3.1% during the 2nd quarter. Vanguard Group Inc. now owns 53,527,210 shares of the biopharmaceutical company’s stock valued at $6,951,579,000 after purchasing an additional 1,610,056 shares in the last quarter. State Street Corp boosted its stake in shares of Celgene Corporation by 2.3% during the 1st quarter. State Street Corp now owns 32,473,417 shares of the biopharmaceutical company’s stock valued at $4,040,668,000 after purchasing an additional 723,844 shares in the last quarter. Jennison Associates LLC boosted its stake in shares of Celgene Corporation by 1.2% during the 2nd quarter. Jennison Associates LLC now owns 13,415,734 shares of the biopharmaceutical company’s stock valued at $1,742,301,000 after purchasing an additional 156,864 shares in the last quarter. Finally, FMR LLC boosted its stake in shares of Celgene Corporation by 5.9% during the 2nd quarter. FMR LLC now owns 12,594,467 shares of the biopharmaceutical company’s stock valued at $1,635,643,000 after purchasing an additional 697,250 shares in the last quarter. 79.24% of the stock is currently owned by hedge funds and other institutional investors.

Celgene Corporation Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Analyst Recommendations for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply